Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have been assigned an average recommendation of “Buy” from the twenty ratings firms that are presently covering the stock, Marketbeat Ratings reports. Twenty equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $48.40.

A number of brokerages have issued reports on GH. Canaccord Genuity Group upped their price objective on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. JPMorgan Chase & Co. increased their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler increased their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Guggenheim restated a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th.

Guardant Health Stock Performance

GH stock opened at $39.32 on Friday. The firm has a fifty day moving average price of $41.88 and a 200 day moving average price of $32.32. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The firm has a market cap of $4.85 billion, a PE ratio of -11.04 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities analysts predict that Guardant Health will post -2.9 EPS for the current year.

Insider Activity

In other news, Director Musa Tariq sold 2,320 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 2,668 shares of company stock worth $95,208. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of hedge funds have recently bought and sold shares of GH. NewEdge Advisors LLC boosted its holdings in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after buying an additional 230 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock valued at $377,000 after acquiring an additional 391 shares during the last quarter. Arizona State Retirement System grew its holdings in Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock worth $1,089,000 after purchasing an additional 403 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Guardant Health by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after purchasing an additional 817 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.